RxDoctor Payments Data

David Zimmerman, MD

Internal Medicine · Huntsville, ARNPI 1346772050

Payments from drug & device makers

$624in general payments, 2019–2025

Across 34 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$190
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$93
  • Alkermes, Inc.$59
  • AbbVie$44
  • Vanda Pharmaceuticals Inc.$43
  • Seagen Inc.$23
  • plus $172 from 10 others

What the payments were for

  • Food & beverage$624100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$624 in reported general payments places this provider in the 65th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$2,179
Medicare patients
53
Services billed
124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban57$72,410
JardianceEmpagliflozin62$61,667
OzempicSemaglutide44$43,629
RybelsusSemaglutide26$34,488
Breztri AerosphereBudesonide/Glycopyr/Formoterol44$32,124
Soliqua 100-33Insulin Glargine/Lixisenatide31$27,480
JanuviaSitagliptin Phosphate14$24,033
XareltoRivaroxaban22$21,825
Spiriva RespimatTiotropium Bromide20$16,307
Stiolto RespimatTiotropium Br/Olodaterol Hcl30$14,304
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,753
MyrbetriqMirabegron17$13,419
FarxigaDapagliflozin Propanediol11$11,537
Novolog FlexpenInsulin Aspart42$9,032
EntrestoSacubitril/Valsartan13$8,789

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$20$78,11770 claims
Johnson & JohnsonXarelto, Invokana$18$28,17833 claims
NovartisEntresto$19$8,78913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Huntsville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →